Clinical Trial News and Research

RSS

EJSO publishes results from Cytori breast reconstruction cell therapy trial

Cytori Therapeutics announced today the publication of RESTORE-2 trial results in the peer-reviewed European Journal of Surgical Oncology.

20 Mar 2012

Positive data from XENTION's XEN-D0103 phase 1 trial on AF

XENTION LTD, the Cambridge-based biopharmaceutical company specialising in the discovery and development of ion channel-modulating drugs, reported positive data today from a phase 1 trial of XEN-D0103 administered orally.

20 Mar 2012

Mayo Clinic researchers train mouse immune systems to eradicate skin cancer from within

Mayo Clinic researchers have trained mouse immune systems to eradicate skin cancer from within, using a genetic combination of human DNA from melanoma cells and a cousin of the rabies virus. The strategy, called cancer immunotherapy, uses a genetically engineered version of the vesicular stomatitis virus to deliver a broad spectrum of genes derived from melanoma cancer cells directly into tumors.

20 Mar 2012

FHCRC research represents potential breakthrough in treatment of pancreas cancer

Pancreas cancer tumors spread quickly and are notoriously resistant to treatment, making them among the deadliest of malignancies. Their resistance to chemotherapy stems in part from a unique biological barrier the tumor builds around itself. Now scientists at Fred Hutchinson Cancer Research Center have found a way to break through that defense, and their research represents a potential breakthrough in the treatment of pancreas cancer.

20 Mar 2012

New information on efficacy of CLA in treating Crohn's disease

The Nutritional Immunology and Molecular Medicine Laboratory (NIMML) research team at Virginia Tech has discovered important new information on the efficacy of conjugated linoleic acid (CLA) in treating Crohn's disease, a form of inflammatory bowel disease (IBD). CLA is a naturally occurring acid found in meat and dairy products known for its anti-cancer and immune modulatory properties.

20 Mar 2012

TB Alliance launches new combination drug trial

In an ambitious effort to stem the dangerous tide of tuberculosis (TB) and deadly drug-resistant TB around the world, TB Alliance today announced that it has launched a first-of-its-kind clinical trial to test a novel drug combination – in both patients who have TB and those who have multidrug-resistant TB (MDR-TB).

19 Mar 2012

Groundbreaking cystic fibrosis clinical trial to proceed after renewed funding

The team of scientists based in Edinburgh, Oxford and London were developing a treatment which involves putting genes into the lungs of patients suffering the fatal, inherited wasting disease, passed early clinical trials in 2010. But the recession badly affected the Cystic Fibrosis Trust, the charity that had funded the programme, and work had to stop last year just as the consortium was closing in on its goal.

19 Mar 2012

Medidata names EXTEDO as technology partner

Medidata Solutions has further expanded its Partner Program by naming EXTEDO, provider of regulatory information management software and service solutions, a Medidata Technology Partner. EXTEDO created an integration that utilizes Medidata Rave Safety Gateway to transfer critical safety data from Medidata Rave, a leading system for electronic data capture, clinical data management and reporting, into its PcVmanager drug safety management solution.

19 Mar 2012

Alnylam commences dosing in ALN-TTR02 Phase I clinical trial for TTR-mediated amyloidosis

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has initiated dosing in its Phase I clinical trial with ALN-TTR02, an RNAi therapeutic targeting the transthyretin (TTR) gene for the treatment of TTR-mediated amyloidosis (ATTR). The study is aimed at evaluating the safety and tolerability of ALN-TTR02 in healthy volunteers.

19 Mar 2012

Convergence initiates CNV1014802 Phase II study in trigeminal neuralgia

Convergence Pharmaceuticals Limited, the company focused on the development of novel and high value analgesic medicines, today announced that the Phase II proof of concept study for CNV1014802 for the treatment of pain associated with trigeminal neuralgia (TN) has started.

19 Mar 2012

FDA approves IDE for HeartWare 'ADVANCE' bridge-to-transplant clinical trial

HeartWare International, Inc., a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that the U.S. Food and Drug Administration has approved an IDE Supplement that allows HeartWare to enroll a fourth allotment, of 54 additional patients, in its "ADVANCE" bridge-to-transplant clinical trial under a Continued Access Protocol.

17 Mar 2012

Oral BRAF inhibitor can extend survival to 16 months for patients with MM

An international team of researchers from the United States and Australia, including researchers at Moffitt Cancer Center in Tampa, Fla., have found that the oral BRAF inhibitor vemurafenib (PLX4032) when tested in a phase II clinical trial offered a high rate of response in patients with previously treated metastatic melanoma and who had the BRAF mutation.

17 Mar 2012

PFO closure device no better than drugs alone in preventing recurrent strokes or TIAs

Loyola University Medical Center is one of the major enrollers in a landmark clinical trial that found that plugging a hole in the heart works no better than drugs in preventing strokes.

17 Mar 2012

Results from AspenBio Pharma's AppyScore trial on appendicitis to be presented at SAEM meeting

The results from AspenBio Pharma's 503-patient pilot study of AppyScore will be presented from the podium the upcoming West Region meeting of the Society for Academic Emergency Medicine (SAEM) being held in Las Vegas, March 16-17.

17 Mar 2012

Repligen total revenue increases to $7,165,000 for quarter ended December 31, 2011

Repligen Corporation today reported financial results for the quarter and nine-month fiscal year ended December 31, 2011.

17 Mar 2012

SK Biopharmaceuticals initiates YKP10811 phase 2 trial in chronic constipation

SK Biopharmaceuticals, a South Korean pharmaceutical company, announced today that the first patient was dosed in a phase 2 clinical trial in the US for patients suffering with chronic constipation using their new chemical entity YKP10811.

17 Mar 2012

Older women with mild retinopathy more likely to have cognitive decline and related vascular changes

Women 65 or older who have even mild retinopathy, a disease of blood vessels in the retina, are more likely to have cognitive decline and related vascular changes in the brain, according to a multi-institutional study led by scientists at the University of California, San Francisco (UCSF).

16 Mar 2012

EORTC, EASL publish first joint CPGs on management of hepatocellular carcinoma

The European Association for the Study of the Liver (EASL) and the European Organisation for Research and Treatment of Cancer (EORTC) today publish their first joint Clinical Practice Guidelines (CPGs) on the management of hepatocellular carcinoma.

16 Mar 2012

Kyolic AGE may reduce duration of cold and flu symptoms by 61%

Americans looking to impact their cold and flu symptoms this season may have a new weapon at their disposal. A randomized, double-blind, placebo-controlled study just published by the University of Florida determined that Kyolic Aged Garlic Extract (AGE) may reduce the duration of symptoms associated with common colds or flus by as much as 61 percent.

16 Mar 2012

$Health Canada grants license to Medtronic DBS Therapy for refractory epilepsy$

Health Canada grants license to Medtronic DBS Therapy for refractory epilepsy

Medtronic, Inc. today announced that it has received from Health Canada a license for Medtronic Deep Brain Stimulation (DBS) Therapy for refractory epilepsy patients.

From Medtronic 16 Mar 2012

Clinical Trial News and Research

EJSO publishes results from Cytori breast reconstruction cell therapy trial

Positive data from XENTION's XEN-D0103 phase 1 trial on AF

Mayo Clinic researchers train mouse immune systems to eradicate skin cancer from within

FHCRC research represents potential breakthrough in treatment of pancreas cancer

New information on efficacy of CLA in treating Crohn's disease

TB Alliance launches new combination drug trial

Groundbreaking cystic fibrosis clinical trial to proceed after renewed funding

Medidata names EXTEDO as technology partner

Alnylam commences dosing in ALN-TTR02 Phase I clinical trial for TTR-mediated amyloidosis

Convergence initiates CNV1014802 Phase II study in trigeminal neuralgia

FDA approves IDE for HeartWare 'ADVANCE' bridge-to-transplant clinical trial

Oral BRAF inhibitor can extend survival to 16 months for patients with MM

PFO closure device no better than drugs alone in preventing recurrent strokes or TIAs

Results from AspenBio Pharma's AppyScore trial on appendicitis to be presented at SAEM meeting

Repligen total revenue increases to $7,165,000 for quarter ended December 31, 2011

SK Biopharmaceuticals initiates YKP10811 phase 2 trial in chronic constipation

Older women with mild retinopathy more likely to have cognitive decline and related vascular changes

EORTC, EASL publish first joint CPGs on management of hepatocellular carcinoma

Kyolic AGE may reduce duration of cold and flu symptoms by 61%

Health Canada grants license to Medtronic DBS Therapy for refractory epilepsy

Event guide: 15th World Clinical Biomarkers & CDx Europe eBook

Latest eBooks

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Driving innovation in Korean drug development

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer